Market Closed -
Canadian Securities Exchange
12:30:34 2024-07-10 pm EDT
|
5-day change
|
1st Jan Change
|
0.02
CAD
|
+33.33%
|
|
+33.33%
|
-63.64%
|
Fiscal Period: October |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
54.85
|
57.4
|
24.48
|
5.969
|
Enterprise Value (EV)
1 |
26.94
|
40.28
|
15.39
|
1.258
|
P/E ratio
|
-7.44
x
|
-7.1
x
|
-1.17
x
|
-0.78
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
10.1
x
|
13.9
x
|
6.28
x
|
1.18
x
|
EV / Revenue
|
4.95
x
|
9.79
x
|
3.95
x
|
0.25
x
|
EV / EBITDA
|
-3.72
x
|
-6.71
x
|
-2.2
x
|
-0.21
x
|
EV / FCF
|
-14,335,704
x
|
-8,013,662
x
|
-4,055,738
x
|
-544,112
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
1.53
x
|
1.02
x
|
0.69
x
|
0.2
x
|
Nbr of stocks (in thousands)
|
99,723
|
123,449
|
122,400
|
119,389
|
Reference price
2 |
0.5500
|
0.4650
|
0.2000
|
0.0500
|
Announcement Date
|
3/1/21
|
3/22/22
|
2/28/23
|
2/29/24
|
Fiscal Period: October |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
8.346
|
5.611
|
5.445
|
4.116
|
3.897
|
5.065
|
EBITDA
1 |
0.3959
|
-1.857
|
-7.235
|
-6.007
|
-7.003
|
-6.037
|
EBIT
1 |
0.3856
|
-1.875
|
-7.576
|
-6.642
|
-7.937
|
-7.086
|
Operating Margin
|
4.62%
|
-33.41%
|
-139.14%
|
-161.37%
|
-203.64%
|
-139.9%
|
Earnings before Tax (EBT)
1 |
-0.6789
|
-6.815
|
-7.426
|
-7.101
|
-20.95
|
-7.711
|
Net income
1 |
-0.6846
|
-6.82
|
-7.431
|
-7.107
|
-20.96
|
-7.721
|
Net margin
|
-8.2%
|
-121.56%
|
-136.47%
|
-172.66%
|
-537.79%
|
-152.43%
|
EPS
2 |
-0.0137
|
-0.1353
|
-0.0739
|
-0.0655
|
-0.1707
|
-0.0638
|
Free Cash Flow
|
-
|
2.558
|
-1.879
|
-5.026
|
-3.795
|
-2.312
|
FCF margin
|
-
|
45.6%
|
-34.52%
|
-122.12%
|
-97.36%
|
-45.64%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/20
|
2/28/20
|
3/1/21
|
3/22/22
|
2/28/23
|
2/29/24
|
Fiscal Period: October |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
4.31
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
33.1
|
27.9
|
17.1
|
9.09
|
4.71
|
Leverage (Debt/EBITDA)
|
10.88
x
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
2.56
|
-1.88
|
-5.03
|
-3.79
|
-2.31
|
ROE (net income / shareholders' equity)
|
-
|
-36%
|
-20.1%
|
-15.4%
|
-45.6%
|
-23.7%
|
ROA (Net income/ Total Assets)
|
-
|
-4.72%
|
-11.9%
|
-8.57%
|
-10%
|
-12.4%
|
Assets
1 |
-
|
144.4
|
62.66
|
82.93
|
209.4
|
62.36
|
Book Value Per Share
2 |
-0
|
0.3800
|
0.3600
|
0.4600
|
0.2900
|
0.2500
|
Cash Flow per Share
2 |
0.0200
|
0.3500
|
0.2800
|
0.1400
|
0.0800
|
0.0400
|
Capex
1 |
0.02
|
0.39
|
0.28
|
0.43
|
0.17
|
0.06
|
Capex / Sales
|
0.25%
|
6.91%
|
5.09%
|
10.46%
|
4.31%
|
1.23%
|
Announcement Date
|
2/28/20
|
2/28/20
|
3/1/21
|
3/22/22
|
2/28/23
|
2/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -63.64% | 1.75M | | +25.83% | 46.56B | | +45.38% | 41.67B | | +0.69% | 41.16B | | +30.52% | 32.4B | | +22.30% | 28.18B | | -6.35% | 28.1B | | +49.25% | 14.52B | | +49.18% | 13.74B | | +3.45% | 12.17B |
Other Biotechnology & Medical Research
|